UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug acalabrutinib takes on standard combo in untreated CLL
Disease control OngoingThis Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…
Matched conditions: UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug break improve CLL treatment for frail patients?
Disease control OngoingThis study looks at whether older, frail patients with untreated chronic lymphocytic leukemia (CLL) can safely stop taking the targeted drug acalabrutinib after 18 months and then restart it if their disease comes back. The goal is to reduce long-term side effects and the risk of…
Matched conditions: UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC